Stock Analysts

Earning Scorecard: RadioShack (RSH) (VZ)

RadioShack Corp. ( RSH ) reported disappointing third quarter 2011 financial results, falling short of the Zacks Consensus Estimates. The comparable store sales for the company-operated stores and kiosks (stores and kiosks opened at least a year) declined 4% year over year […]

Stock Analysts

Earnings Preview: Covidien (BCR) (BDX) (COV) (JNJ)

Leading health care products maker Covidien plc ( COV ) is scheduled to release its fourth-quarter fiscal 2011 results on Tuesday, November 15. The Ireland-based company expects net sales for fiscal 2011 to grow 8% to 11% year over year. Analysts polled by Zacks are currently looking for earnings per share of $1.05 and $3.94 on average for the fourth quarter and fiscal 2011, respectively […]

Stock Analysts

Keep an Eye on AUXILIO (AUXO)

Keep an Eye on AUXILIO Ken Nagy, CFA AUXILIO ( AUXO ) is the only health care exclusive, vendor neutral Managed Print Services (MPS) firm that provides document production management strategies, services and solutions to hospitals throughout the United States. AUXILIO’s continuous workflow improvement solutions enable hospitals and health systems to reduce costs and waste in their operational and clinical functions by managing the process of document production between printing and copying equipment and technology. […]

Stock Analysts

Earnings Scorecard: Cardinal (ABC) (CAH) (CFN) (MCK)

Cardinal Health ( CAH ) reported first-quarter fiscal 2011 (ended September 30) adjusted (excluding one-time expenses) earnings per share from continuing operations of 73 cents, exceeding the Zacks Consensus Estimate of 72 cents as well as the year-ago figure of 66 cents. Earnings from continuing operations (as reported) dropped about 19% year over year to $237.1 million (or 68 cents a share) reflecting a previous-year gain (of 21 cents) from the sale of CareFusion ( CFN ) shares. […]

Stock Analysts

Roche Eyes Cancer Drug Approval (CRIS) (RHHBY)

Roche Holdings Ltd. ( RHHBY ) recently announced that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for vismodegib for review. The company is seeking approval of vismodegib for the treatment of patients with advanced basal cell carcinoma (BCC), whose lesions could not be operated or for whom surgery would result in substantial deformity […]

Technicals

Bearish MACD for Calgon Carbon – Tale of the Tape (CCC)

Calgon Carbon Corporation ’s ( CCC ) MACD indicator has entered into bearish territory with a reading of -0.0441. The Zacks #4 Rank (“Sell”) stock decreased slightly to $14.76 in morning trade. The Zacks Consensus Estimate for the year ending December 2011 has decreased by 5 cents over the past month to 76 cents per share […]